413 Age is not Associated With Adverse Events From Biologic Therapy in Patients With Inflammatory Bowel Disease

Published on May 1, 2010in Gastroenterology17.373
· DOI :10.1016/S0016-5085(10)60281-8
Anita Bhushan1
Estimated H-index: 1
,
Darrell S. Pardi63
Estimated H-index: 63
+ 6 AuthorsWilliam J. Sandborn182
Estimated H-index: 182
Sources
Abstract
📖 Papers frequently viewed together
254 Citations
790 Citations
7 Citations
References0
Newest
Cited By10
Newest
#1Nienke Z. Borren (Harvard University)H-Index: 8
#2Ashwin N. Ananthakrishnan (Harvard University)H-Index: 74
Background & Aims Management of immune-mediated inflammatory diseases often requires lifelong immunosuppression. Increasing numbers of older patients have inflammatory diseases and are particularly vulnerable to risks of immune suppressive therapies—particularly infections and malignancies. Methods We systematically searched PubMed/Medline and Embase to identify eligible studies that examined the safety of biologic therapies in older patients with immune-mediated inflammatory diseases (inflammat...
39 CitationsSource
#1Jörg Mahlich (HHU: University of Düsseldorf)H-Index: 14
#2Katsuyoshi Matsuoka (Toho University)H-Index: 12
Last. Rosarin Sruamsiri (NU: Naresuan University)H-Index: 14
view all 3 authors...
There is little information regarding the use of biologics in Inflammatory Bowel Disease (IBD) patients in Japan. The aim of this study was to determine the factors associated with the use of biologics in the treatment of Japanese patients with IBD. An online survey was conducted among Japanese patients with IBD (n = 1035). Socioeconomic as well as treatment related information was collected. Logistic regression was applied to analyze the determinants of biologic treatment. Younger age (≤ 40 yea...
4 CitationsSource
#1Natasha Bollegala (U of T: University of Toronto)H-Index: 10
#2Tim Jackson (U of T: University of Toronto)H-Index: 58
Last. Geoffrey C. Nguyen (U of T: University of Toronto)H-Index: 54
view all 3 authors...
Background & Aims Elderly patients may be at increased risk for poor outcomes after surgery for inflammatory bowel disease (IBD). We investigated postoperative mortality and the incidence of complications in elderly patients with IBD. Methods We identified patients who underwent major IBD-related abdominal surgery using the American College of Surgeons National Surgical Quality Improvement Program Participant Use Files, from 2005 through 2012. We compared mortality and postoperative complication...
43 CitationsSource
#1Alyssa M. Parian (Johns Hopkins University)H-Index: 16
#2Christina Ha (Johns Hopkins University)H-Index: 17
Older Americans, aged 65 years and above, represent the fastest growing age group with an estimated 31% increase in the number of older persons during this decade.1 This elderly subgroup, partly due to the implementation of Medicare Part D, also represents the largest consumers of prescription medications with an increased risk of medication-related adverse effects.2,3 Older age is associated with greater comorbidity and polypharmacy, which can add to the risk for medication interactions and adv...
37 CitationsSource
Anti-tumor necrosis factor-α (TNF) agents, including infliximab, adalimumab, and certolizumab pegol, are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life, and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative effectiveness of different agents, as well as better understandin...
32 CitationsSource
#1Christina Ha (UCLA: University of California, Los Angeles)H-Index: 17
Accumulating evidence has demonstrated improved clinical outcomes with earlier initiation of immunosuppressive therapy for patients with inflammatory bowel disease (IBD). However, current evidence-based treatment paradigms are not often applied to the older IBD patients, as they represent a higher-risk group for disease and medication-associated complications, particularly infection. Serious infections, associated with increased hospitalizations, morbidity, and mortality, are more common among t...
5 CitationsSource
#1Christina Ha (UCLA: University of California, Los Angeles)H-Index: 17
#2Seymour Katz (NYU: New York University)H-Index: 35
The management of inflammatory bowel disease (IBD) in elderly patients provides added complexity for healthcare providers who need to take into account the high likelihood of co-morbid disease, the need for polypharmacy and, in many instances, greater patient fragility. While biologics are often considered first-line corticosteroid-sparing strategies for moderate to severe disease, the additional variables unique to an elderly patient warrant consideration when discussing IBD therapeutics. As ch...
6 CitationsSource
#1Christina HaH-Index: 17
#2Seymour Katz (North Shore University Hospital)H-Index: 35
The management of inflammatory bowel disease in the older patient extends beyond the gastrointestinal tract. Pre-existing comorbidities, polypharmacy, functional status and physical reserve can impact disease course, response to therapy and quality of life. Current therapeutic endpoints may not be as immediately applicable to the older IBD patient at higher risk for adverse outcomes. This review focuses on the latest studies addressing the natural history, clinical course and therapeutic outcome...
21 CitationsSource
#1Vincent Billioud (Nancy-Université)H-Index: 12
#2Laurent Peyrin-Biroulet (Nancy-Université)H-Index: 103
3 CitationsSource
#1Andreas StallmachH-Index: 52
#2Stefan HagelH-Index: 20
Last. Tony BrunsH-Index: 28
view all 7 authors...
Population ageing is a global phenomenon. People aged 65 years and older comprise approximately 16% of the population of Europe. The medical management of elderly patients with inflammatory bowel disease (IBD) is challenging with respect to diagnosis, pharmaceutical and surgical treatment, and complications. IBD has a late onset in 10%–15% of patients, with the first flare occurring at 60 to 70 years of age; others suffer from the disease for several decades. Even though the natural course of th...
43 CitationsSource